Jim Cramer made UnitedHealth Group (NYSE: UNH | UNH Price Prediction) the centerpiece of his April 21 Mad Money show, arguing the managed care giant is back in fighting form after a brutal year. His case was simple: a returning CEO he trusts, a clean Q1 beat, and a stock still trading far below its highs.
“Today, the company reported what I think will be the first of many upside surprises. Just like the way Hemsley always used to do, clockwork. You don’t just get one good quarter from Hemsley, you get many. Stock shot up nearly 7%. I think it’s a buy. I think it can return to its former greatness,” Cramer said.
The math behind his call is the part most investors should focus on.
The $354 Math
UnitedHealth closed at $354.56 on April 23, 2026. On the Q1 call, management raised full-year adjusted EPS guidance to greater than $18.25 per share, up from a prior floor of $17.75. That puts the forward multiple at roughly 19x earnings, in line with the 20x forward P/E Alpha Vantage shows for the stock.
For context, UNH traded above $600 less than a year ago and hit a 52-week high of $412.49. Even after a 30.22% one-month rally, shares are still down 14.8% over the trailing year. That is the drawdown Cramer believes created the setup.
What Q1 Actually Delivered
UnitedHealth’s Q1 2026 8-K showed adjusted EPS of $7.23 versus a $6.61 consensus, a 9.38% beat. Revenue came in at $111.72 billion, up 2.0% year over year. The most important number for investors watching margin repair: the medical care ratio improved 90 basis points to 83.9%, against the 84.8% posted in Q1 2025.
UnitedHealthcare’s operating margin expanded to 6.6%, with segment operating earnings of $5.69 billion and 415,000 net new Employer & Individual members. Operating cash flow hit $8.91 billion, or 1.4x net income, giving CFO Wayne DeVeydt room to accelerate buybacks. Management is now committed to deploying at least $2.0 billion in repurchases by the end of Q2.
The Hemsley Factor
Cramer’s conviction leans heavily on Board Chairman and CEO Stephen Hemsley, who returned to the role in May 2025 after running the company from 2006 to 2017. On the call, Hemsley said UnitedHealth has “refreshed nearly half of our top 100 leadership roles” and is investing nearly $1.5 billion in AI-related initiatives in 2026. He added that the team is “a long way from performing to our full potential.”
The Risks Cramer Didn’t Emphasize
The bull case assumes margin repair continues, but Q1 still showed cracks. Medicare Advantage membership dropped 965,000, and Medicaid fell 220,000. Optum Health’s revenue declined 3% year over year, and its operating earnings slid to $3.30 billion from $3.89 billion. DOJ actions tied to the Medicare program and residual cyberattack risk remain live overhangs. UnitedHealthcare chief Timothy Noel also warned that “utilization patterns continuing at the high elevated levels that we experienced inside of 2025” are still in play.
At 19x forward earnings, with raised guidance and buybacks accelerating on an “intrinsic value discount,” Cramer’s math checks out. Whether it stays a steal depends on whether the second-half margin cadence holds.
Top Gaining Stocks
Top Losing Stocks